BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sabri MR, Beheshtian E. Comparison of the therapeutic and side effects of tadalafil and sildenafil in children and adolescents with pulmonary arterial hypertension. Pediatr Cardiol 2014;35:699-704. [PMID: 24253611 DOI: 10.1007/s00246-013-0840-z] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Wacker J, Weintraub R, Beghetti M. An update on current and emerging treatments for pulmonary arterial hypertension in childhood and adolescence. Expert Review of Respiratory Medicine 2019;13:205-15. [DOI: 10.1080/17476348.2019.1565998] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Mukherjee D, Konduri GG. Pediatric Pulmonary Hypertension: Definitions, Mechanisms, Diagnosis, and Treatment. Compr Physiol 2021;11:2135-90. [PMID: 34190343 DOI: 10.1002/cphy.c200023] [Reference Citation Analysis]
3 Sabri MR, Shoja M, Shoja M, Hosseinzadeh M. The effect of tadalafil on functional capacity and echocardiographic parameters in patients with repaired Tetralogy of Fallot. ARYA Atheroscler 2018;14:177-82. [PMID: 30627194 DOI: 10.22122/arya.v14i4.1561] [Reference Citation Analysis]
4 Beghetti M, Gorenflo M, Ivy DD, Moledina S, Bonnet D. Treatment of pediatric pulmonary arterial hypertension: A focus on the NO-sGC-cGMP pathway. Pediatr Pulmonol 2019;54:1516-26. [PMID: 31313530 DOI: 10.1002/ppul.24442] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
5 Zenitani M, Nojiri T, Uehara S, Miura K, Hosoda H, Kimura T, Nakahata K, Miyazato M, Okuyama H, Kangawa K. C-type natriuretic peptide in combination with sildenafil attenuates proliferation of rhabdomyosarcoma cells. Cancer Med 2016;5:795-805. [PMID: 26816265 DOI: 10.1002/cam4.642] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
6 Wang L, Jia H, Tower RJ, Levine MA, Qin L. Analysis of short-term treatment with the phosphodiesterase type 5 inhibitor tadalafil on long bone development in young rats. Am J Physiol Endocrinol Metab 2018;315:E446-53. [PMID: 29920215 DOI: 10.1152/ajpendo.00130.2018] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
7 Hocq C, Vanhoutte L, Guilloteau A, Massolo AC, Van Grambezen B, Carkeek K, Piersigilli F, Danhaive O; from the European Society for Pediatric Research. Early diagnosis and targeted approaches to pulmonary vascular disease in bronchopulmonary dysplasia. Pediatr Res 2021. [PMID: 33674739 DOI: 10.1038/s41390-021-01413-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Duranti G, Ceci R, Di Luigi L, Antinozzi C, Dimauro I, Sabatini S, Cervelli M, Sgrò P. Effect of Tadalafil Administration on Redox Homeostasis and Polyamine Levels in Healthy Men with High Level of Physical Activity. Int J Environ Res Public Health 2021;18:9962. [PMID: 34639267 DOI: 10.3390/ijerph18199962] [Reference Citation Analysis]
9 Dadlani GH, Sosa P, Cobb H, Akshatha A. Pediatric pulmonary hypertension: diagnosis and management. Curr Opin Cardiol 2016;31:78-87. [PMID: 26569085 DOI: 10.1097/HCO.0000000000000243] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.8] [Reference Citation Analysis]
10 Sabri M, Zolfi-gol A, Ahmadi A, Haghjooy-javanmard S. Effect of Tadalafil on Myocardial and Endothelial Function and Exercise Performance After Modified Fontan Operation. Pediatr Cardiol 2016;37:55-61. [DOI: 10.1007/s00246-015-1238-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
11 Mokra D, Mokry J. Phosphodiesterase Inhibitors in Acute Lung Injury: What Are the Perspectives? Int J Mol Sci 2021;22:1929. [PMID: 33669167 DOI: 10.3390/ijms22041929] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
12 Magee AG, Makhecha S, Bentley S. Risk-benefit considerations when prescribing phosphodiesterase-5 inhibitors in children. Expert Opin Drug Saf 2015;14:633-42. [PMID: 25746065 DOI: 10.1517/14740338.2015.1022527] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
13 Yamazaki H, Kobayashi N, Taketsuna M, Tajima K, Suzuki N, Murakami M. Safety and effectiveness of tadalafil in pediatric patients with pulmonary arterial hypertension: a sub-group analysis based on Japan post-marketing surveillance. Curr Med Res Opin 2017;33:2241-9. [PMID: 28699846 DOI: 10.1080/03007995.2017.1354832] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
14 Sabri MR, Bigdelian H, Hosseinzadeh M, Ahmadi A, Ghaderian M, Shoja M. Comparison of the therapeutic effects and side effects of tadalafil and sildenafil after surgery in young infants with pulmonary arterial hypertension due to systemic-to-pulmonary shunts. Cardiol Young 2017;27:1686-93. [PMID: 28994364 DOI: 10.1017/S1047951117000981] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 1.7] [Reference Citation Analysis]
15 Dhariwal AK, Bavdekar SB. Sildenafil in pediatric pulmonary arterial hypertension. J Postgrad Med 2015;61:181-92. [PMID: 26119438 DOI: 10.4103/0022-3859.159421] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.0] [Reference Citation Analysis]
16 Henrie AM, Nawarskas JJ, Anderson JR. Clinical utility of tadalafil in the treatment of pulmonary arterial hypertension: an evidence-based review. Core Evid 2015;10:99-109. [PMID: 26587013 DOI: 10.2147/CE.S58457] [Cited by in Crossref: 5] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]